Key Takeaways
- Hansa Biopharma plans to list on Nasdaq under ticker HNSA, aiming to expand its U.S. investor base.
- The company recently licensed Idefirix’s rights in Europe and the Middle East for €115 million to focus on the U.S. market.
- The FDA is set to review imlifidase, with a decision expected by December 19, following promising Phase 3 trial results.
Listing Plans and Financial Focus
Hansa Biopharma is seeking a listing on the Nasdaq Global Market under the ticker HNSA, in addition to its existing Nasdaq Stockholm listing. The specific number of securities, pricing, and timing of the offering have yet to be determined, and it’s possible that the offering may not proceed. The company is also contemplating a concurrent private placement in Europe to bolster its funding.
About Idefirix
Idefirix, known as imlifidase, has been conditionally approved in Europe to reduce sensitization in adults prior to kidney transplantation. A recent post-authorization study in Europe has revealed a significant 90% graft failure-free survival rate after one year, laying the groundwork for Hansa’s planned application for full European approval, which is expected to be submitted in the fourth quarter of this year.
Strategic Partnerships and Future Directions
In a strategic move to concentrate on the U.S. market, Hansa has transferred the commercialization rights of Idefirix in Europe and the Middle East to SERB Pharmaceuticals. This licensing deal, valued at €115 million, allows Hansa to redirect its resources more effectively.
The FDA is currently reviewing imlifidase, reflecting positive outcomes from a Phase 3 kidney transplant trial. The decision is anticipated by December 19. However, the proposed U.S. listing hinges on regulatory reviews, market conditions, and investor interest, emphasizing the dynamic nature of Hansa’s strategic approach to expanding its presence in the competitive U.S. biomedical landscape.
The content above is a summary. For more details, see the source article.